Linda L. Kusner

Linda L. Kusner

Auto-generated profile, based on publicly available information

Linda L. Kusner

George Washington University

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
HKHenry Kaminski
Henry Kaminski
PSPatricia Sikorski
Patricia Sikorski
SCS. Isabel Coronel
S. Isabel Coronel
LKLinda L. Kusner
Linda L. Kusner
Myasthenia gravis (MG) stands as a prototypical antibody-mediated autoimmune disease: it is dependent on T cells and characterized by the presence of autoantibodies targeting proteins located on the postsynaptic surface of skeletal muscle, known as the neuromuscular junction. Patients with MG exhibit a spectrum of weakness, ranging from limited ocular muscle involvement to life-threatening respiratory failure. Recent decades have witnessed substantial progress in understanding the underlying pathophysiology, leading to the delineation of distinct subcategories within MG, including MG linked to AChR or MuSK antibodies as well as age-based distinction, thymoma-associated, and immune checkpoint inhibitor–induced MG. This heightened understanding has paved the way for the development of more precise and targeted therapeutic interventions. Notably, the FDA has recently approved therapeutic inhibitors of complement and the IgG receptor FcRn, a testament to our improved comprehension of autoantibody effector mechanisms in MG. In this Review, we delve into the various subgroups of MG, stratified by age, autoantibody type, and histology of the thymus with neoplasms. Furthermore, we explore both current and potential emerging therapeutic strategies, shedding light on the evolving landscape of MG treatment.

14 October 2005 in Muscle & Nerve
Verified
Journal Article
Closed access
PDF file
BHBenjamin W. Hughes
Benjamin W. Hughes
LKLinda L. Kusner
Linda L. Kusner
HKHenry J. Kaminski
Henry J. Kaminski

1 January 2009 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
JŠJindrich Šoltýs
Jindrich Šoltýs
LKLinda L. Kusner
Linda L. Kusner
AYAndrew Young
Andrew Young
CRChelliah Richmonds
Chelliah Richmonds
DHDenise Hatala
Denise Hatala
HKHenry J. Kaminski
Henry J. Kaminski

1 August 2015 in Experimental Neurology
Verified
Journal Article
Open access
MLMario Losen
Mario Losen
PMPilar Martinez
Pilar Martinez
PMPeter C. Molenaar
Peter C. Molenaar
KLKonstantinos Lazaridis
Konstantinos Lazaridis
STSocrates Tzartos
Socrates Tzartos
LKLinda Kusner
Linda Kusner
Myasthenia gravis (MG) with antibodies against the acetylcholine receptor (AChR) is characterized by a chronic, fatigable weakness of voluntary muscles. The production of autoantibodies involves the dysregulation of T cells which provide the environment for the development of autoreactive B cells. The symptoms are caused by destruction of the postsynaptic membrane and degradation of the AChR by IgG autoantibodies, predominantly of the G1 and G3 subclasses. Active immunization of animals with AChR from mammalian muscles, AChR from Torpedo or Electrophorus electric organs, and recombinant or synthetic AChR fragments generates a chronic model of MG, termed experimental autoimmune myasthenia gravis (EAMG). This model covers cellular mechanisms involved in the immune response against the AChR, e.g. antigen presentation, T cell-help and regulation, B cell selection and differentiation into plasma cells. Our aim is to define standard operation procedures and recommendations for the rat EAMG model using purified AChR from the Torpedo californica electric organ, in order to facilitate more rapid translation of preclinical proof of concept or efficacy studies into clinical trials and, ultimately, clinical practice.

28 June 2008 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JŠJindrich Šoltýs
Jindrich Šoltýs
BGBendi Gong
Bendi Gong
HKHenry J. Kaminski
Henry J. Kaminski
YZYuefang Zhou
Yuefang Zhou
LKLinda L. Kusner
Linda L. Kusner

1 February 2016 in Cytokine
Verified
Journal Article
Closed access
YXYanchen Xie
Yanchen Xie
HLHai-Feng Li
Hai-Feng Li
BJBin Jiang
Bin Jiang
YLYao Li
Yao Li
HKHenry Kaminski
Henry Kaminski
LKLinda L. Kusner
Linda L. Kusner